-
1
المؤلفون: Christian U. Blank, John B. A. G. Haanen, Doranne L. Hilarius, Michel W. J. M. Wouters, Willeke A. M. Blokx, Franchette W P J van den Berkmortel, Ellen Kapiteijn, Rawa K. Ismail, Geke A. P. Hospers, Jesper van Breeschoten, Alfonsus J. M. van den Eertwegh, Rozemarijn S. van Rijn, Jan Willem B. de Groot, Maureen J.B. Aarts, D Piersma, Astrid A M van der Veldt, G. Vreugdenhil, Marion A. M. Stevense-den Boer, Marye Boers-Sonderen, Karijn P M Suijkerbuijk, Olivier J. van Not, Melissa M. De Meza
المساهمون: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Medical Oncology, Radiology & Nuclear Medicine, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Internal medicine, Medical oncology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D)
المصدر: International Journal of Cancer, 150(5), 816-824. Wiley
van Not, O J, van Breeschoten, J, van den Eertwegh, A J M, Hilarius, D L, de Meza, M M, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Ismail, R K, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A M, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Blokx, W A M, Suijkerbuijk, K P M & Wouters, M W J M 2022, ' The unfavorable effects of COVID-19 on Dutch advanced melanoma care ', International Journal of Cancer, vol. 150, no. 5, pp. 816-824 . https://doi.org/10.1002/ijc.33833Test
International Journal of Cancer, 150, 816-824
International Journal of Cancer, 150, 5, pp. 816-824
International Journal of Cancer, 150(5), 816-824. Wiley-Liss Inc.
International Journal of Cancer, 150(5), 816-824. WILEY
International Journal of Cancerمصطلحات موضوعية: Adult, Male, advanced melanoma, Cancer Research, Pediatrics, medicine.medical_specialty, Skin Neoplasms, Coronavirus disease 2019 (COVID-19), IMPACT, nationwide registry, Medical care, Systemic therapy, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], systemic therapy, SDG 3 - Good Health and Well-being, COVID‐19, Humans, Medicine, Stage IIIC, Cancer Therapy and Prevention, Melanoma, Aged, Netherlands, Advanced melanoma, Aged, 80 and over, Control period, Performance status, SARS-CoV-2, business.industry, COVID-19, Middle Aged, medicine.disease, clinical outcomes, Oncology, Female, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6999d1436b905ac42aa992a91b031b28Test
https://hdl.handle.net/2066/244556Test -
2
المؤلفون: Maurits L. van Montfoort, Daniel J. Vis, Kees Hendricksen, Nick van Dijk, Laura A. Smit, Michiel S. van der Heijden, Henk G. van der Poel, Maries van den Broek, Christian U. Blank, Annemarie Bruining, Yoni Lubeck, Lodewyk F. A. Wessels, Dennis Peters, Pia Kvistborg, Karina Silina, Ton N. Schumacher, Charlotte van Rooijen, Karolina Sikorska, Erik Hooijberg, Annegien Broeks, Bas W.G. van Rhijn, Alberto Gil-Jimenez, Jeantine M de Feijter, Thierry N. Boellaard
المساهمون: University of Zurich, van der Heijden, Michiel S, Graduate School
المصدر: Nature medicine, 26(12), 1839-1844. Nature Publishing Group
مصطلحات موضوعية: Adult, Male, 0301 basic medicine, medicine.medical_specialty, medicine.medical_treatment, Programmed Cell Death 1 Receptor, 610 Medicine & health, Ipilimumab, 10263 Institute of Experimental Immunology, Gastroenterology, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, 1300 General Biochemistry, Genetics and Molecular Biology, Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Humans, Medicine, CTLA-4 Antigen, Stage (cooking), Adverse effect, Aged, Neoplasm Staging, business.industry, Antibodies, Monoclonal, General Medicine, Immunotherapy, Middle Aged, Clinical trial, Nivolumab, 030104 developmental biology, 030220 oncology & carcinogenesis, Monoclonal, 570 Life sciences, biology, Female, Urothelium, business, medicine.drug
وصف الملف: 2020_van_Dijk_Nat_Med.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0413d513e2c90df2d190163c39a4236dTest
http://www.scopus.com/inward/record.url?scp=85092396181&partnerID=8YFLogxKTest -
3
المؤلفون: Christian U. Blank, Stéphane Dalle, Alexander M.M. Eggermont, Sandrine Marreaud, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Stefan Suciu, Nageatte Ibrahim, Rahima Jamal, Paolo A. Ascierto, Alexander C.J. van Akkooi, Michal Kicinski, Piotr Rutkowski, Georgina V. Long, Dirk Schadendorf, Ralf Gutzmer, Shahneen Sandhu, Andrew Haydon, Victoria Atkinson, Susana Puig, Adnan Khattak, Anna Maria Di Giacomo, Clemens Krepler, Mario Mandalà, Rutger H. T. Koornstra, Caroline Robert, Jean-Jacques Grob, Leonel Hernandez-Aya, Paul Lorigan, James Larkin
المساهمون: Medical oncology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology
المصدر: Jama Oncology, 6, 519-527
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 519-527 . https://doi.org/10.1001/jamaoncol.2019.5570Test
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2019.5570Test
Jama Oncology, 6, 4, pp. 519-527
JAMA Oncology, 6(4), 519-527. American Medical Associationمصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Population, Medizin, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, Disease-Free Survival, law.invention, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Medicine, Humans, 030212 general & internal medicine, education, Adverse effect, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, education.field_of_study, Manchester Cancer Research Centre, business.industry, Proportional hazards model, ResearchInstitutes_Networks_Beacons/mcrc, Hazard ratio, Middle Aged, Ipilimumab, Clinical trial, Oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b431bc34ae329792ac7bd923376806Test
https://hdl.handle.net/2066/218502Test -
4
المؤلفون: Sanne Patiwael, Christian U. Blank, Ton N. Schumacher, Antoni Ribas, John B. A. G. Haanen, Anastasia Gangaev, Daisy Philips, Dirk Schadendorf, Joost H. van den Berg, Maartje W. Rohaan, Bastian Schilling, Elisa A. Rozeman, Pia Kvistborg, Olga I. Isaeva
المصدر: Proc Natl Acad Sci U S A
Proceedings of the National Academy of Sciences of the United States of America, vol 118, iss 43مصطلحات موضوعية: Male, Receptors, Antigen, T-Cell, alpha-beta, Programmed Cell Death 1 Receptor, Medizin, Epitopes, T-Lymphocyte, CD8-Positive T-Lymphocytes, Lymphocyte Activation, Epitope, Cohort Studies, Epitopes, melanoma-reactive CD8 T cells, Receptors, PD-1, 80 and over, Cytotoxic T cell, CTLA-4 Antigen, Hepatitis A Virus Cellular Receptor 2, Immune Checkpoint Inhibitors, Melanoma, Cancer, alpha-beta, Aged, 80 and over, Multidisciplinary, Middle Aged, Biological Sciences, medicine.anatomical_structure, 5.1 Pharmaceuticals, Antigen, Female, Development of treatments and therapeutic interventions, medicine.symptom, Melanoma-Specific Antigens, Adult, Receptors, CXCR5, T cell, In Vitro Techniques, Clinical Research, medicine, Humans, Aged, business.industry, Compartment (ship), T-Cell, medicine.disease, CXCR5, Blockade, Kinetics, T-Lymphocyte, Mechanism of action, CTLA-4, Cancer research, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::994323e563648a11d8ffa0127b701604Test
https://doi.org/10.1073/pnas.2102849118Test -
5
المؤلفون: Christoph Hoeller, Marie-Francoise Avril, Pietro Quaglino, François Aubin, Lars Bastholt, Takashi Inozume, Virginia Ferraresi, Michael B. Jameson, Kevin B. Kim, Oliver Bechter, Dirk Schadendorf, Kenji Yokota, Carmen Loquai, Maria-Jose Passos, Inge Marie Svane, Michele Maio, Catherine Barrow, Frank Meiss, Nageatte Ibrahim, Andrzej Mackiewicz, Phillip Parente, Tatsuya Takenouchi, Caroline Dutriaux, Piotr Rutkowski, Alfonsus J M van den Eertwegh, Paola Queirolo, Catriona M. McNeil, Peter Mohr, Felix Kiecker, Susana Puig, Friedegund Meier, Lutz Kretschmer, Alexander C.J. van Akkooi, Alex Menzies, Timothy Crook, Christian U. Blank, Suzana Matkovic, Michael C. Brown, Ragini R. Kudchadkar, Max Levin, Rüdiger Hein, Tanja Skytta, Gerald P. Linette, Clemens Krepler, Adnan Khattak, Ernest Marshall, Joseph Kerger, Oddbjorn Straume, Laurent Mortier, Jochen Utikal, Micaela Hernberg, James Larkin, Yoshio Kiyohara, Mario Mandalà, Henrik Schmidt, Daniil Stroyakovskiy, Pablo Luis Ortiz Romero, Naoya Yamazaki, John Walker, Anna Maria Di Giacomo, Lionel Geoffrois, Jean-Philippe Lacour, Caroline Robert, Vincent Descamps, Shahneen Sandhu, Gil Bar-Sela, Paul C. Nathan, Marcin Dzienis, Ralf Gutzmer, Claus Garbe, Andrey Meshcheryakov, Patrick Combemale, Martin Fehr, Guzel Mukhametshina, Helena Kapiteijn, Geke A. P. Hospers, Jun Aoi, Andrew Haydon, Rutger H. T. Koornstra, Marie-Thérèse Leccia, Sigrun Hallmeyer, Pier Francesco Ferrucci, Jean-Jacques Grob, Leonel Hernandez-Aya, Jan-Christoph Simon, Vanna Chiarion Sileni, Alain Algazi, Lidija Sekulovic, Sandrine Marreaud, Bernard Fitzharris, Jacob Schachter, Xinni Song, Wolf-Henning Boehncke, Rahima Jamal, Paul Lorigan, Maureen J.B. Aarts, Reinhard Dummer, Mike McCrystal, César Martins, Reiner Hofmann-Wellenhof, Alexander M.M. Eggermont, Carola Berking, Elaine Dunwoodie, Bernard Guillot, Michal Kicinski, Philippe Saiag, Céleste Lebbé, Thierry Lesimple, Stefan Suciu, Michal Lotem, Paula Ferreira, Mohammed M. Milhem, Laurent Machet, Patrick Terheyden, Anna Katharina Winge-Main, Peter Hersey, Jean-Francois Baurain, Axel Hauschild, Stéphane Dalle, Jean-Philippe Arnault, Paolo A. Ascierto, Gerard Groenewegen, Florent Grange, Georgina V. Long, Victoria Atkinson, Philippa Corrie, Matteo S. Carlino, Thomas Jouary, Daniel Hendler, Richard Casasola, Ashita Waterston, Jessica C. Hassel
المساهمون: University Medical Center [Utrecht], Azienda Ospedaliera Ospedale Papa Giovanni XXIII [Bergamo, Italy], The University of Sydney, Princess Alexandra Hospital, Brisbane, University of Queensland [Brisbane], Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), N.N. Blokhin National Medical Research Center of Oncology, Edith Cowan University (ECU), Royal Marsden NHS Foundation Trust, Universitat de Barcelona (UB), Instituto de Salud Carlos III [Madrid] (ISC), Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Universitätsklinikum Essen [Universität Duisburg-Essen] (Uniklinik Essen), Radboud University Medical Center [Nijmegen], Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), University Hospital of Siena, Amsterdam UMC - Amsterdam University Medical Center, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hannover Medical School [Hannover] (MHH), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), The Christie NHS Foundation Trust [Manchester, Royaume-Uni], Merck & Co. Inc, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Institut Gustave Roussy (IGR), Oncologie dermatologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Internal medicine, CCA - Cancer Treatment and quality of life
المصدر: EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 643-654 . https://doi.org/10.1016/S1470-2045Test(21)00065-6
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Groupمصطلحات موضوعية: Male, Skin Neoplasms, Medizin, Pembrolizumab, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], MESH: Aged, 80 and over, 0302 clinical medicine, Randomized controlled trial, law, Monoclonal, 80 and over, MESH: Double-Blind Method, 030212 general & internal medicine, Neoplasm Metastasis, Humanized, Melanoma, MESH: Aged, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Hazard ratio, MESH: Neoplasm Staging, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Female, Adult, Aged, Antibodies, Monoclonal, Humanized, Double-Blind Method, Humans, Neoplasm Staging, medicine.medical_specialty, MESH: Melanoma, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Placebo, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Adjuvant therapy, education, Cancer staging, MESH: Humans, business.industry, MESH: Skin Neoplasms, MESH: Adult, MESH: Neoplasm Metastasis, MESH: Male, Clinical trial, MESH: Antibodies, Monoclonal, Humanized, business, MESH: Female
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca46af8de45fdf5ffd9d70f717e94208Test
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027Test -
6
المؤلفون: Michel W.J.M. Wouters, Sandra Adriaansz, Christian U. Blank, Bernies van der Hiel, Willem M.C. Klop, Bart A. van de Wiel, Johannes V. Van Thienen, Stephanie A. Blankenstein, Karolina Sikorska, Harm van Tinteren, Maartje W. Rohaan, Alexander C.J. van Akkooi, Winan J. van Houdt, Sofie Wilgenhof, Max J. Lahaye, A. Sari, Lindsay G Grijpink-Ongering, John B. A. G. Haanen
المصدر: Annals of Surgery, 274(2), 383-389. LIPPINCOTT WILLIAMS & WILKINS
مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, medicine.medical_treatment, unresectable, Pyrimidinones, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Interquartile range, Positron Emission Tomography Computed Tomography, Antineoplastic Combined Chemotherapy Protocols, Oximes, medicine, Humans, Stage IIIC, Prospective Studies, Melanoma, Cancer staging, Aged, Neoplasm Staging, Netherlands, Trametinib, business.industry, neoadjuvant, MEK inhibitor, Imidazoles, Dabrafenib, Cytoreduction Surgical Procedures, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Neoadjuvant Therapy, BRAF mutation, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Surgery, Female, Radiology, business, medicine.drug
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45c8330f3776251538255964ce6c8db0Test
https://pubmed.ncbi.nlm.nih.gov/33843797Test -
7
المؤلفون: John B. A. G. Haanen, Kees Hendricksen, Axel Bex, Patricia J. Zondervan, Teele Kuusk, Niels M. Graafland, Johan V. Van Thienen, Sofie Wilgenbos, Christian U. Blank, Mariette Schrier, Brunolf W. Lagerveld, Jeroen Van Moorselaar
المساهمون: CCA - Cancer Treatment and quality of life, Urology, Graduate School, APH - Personalized Medicine, APH - Quality of Care
المصدر: Bex, A, Van Thienen, J V, Schrier, M, Graafland, N, Kuusk, T, Hendricksen, K, Lagerveld, B, Zondervan, P, van Moorselaar, J R A, Blank, C, Wilgenbos, S & Haanen, J 2019, ' A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX) ', Future Oncology, vol. 15, no. 19, pp. 2203-2209 . https://doi.org/10.2217/fon-2019-0111Test
Future Oncology, 15(19), 2203-2209. Future Medicine Ltd.
Future oncology (London, England), 15(19), 2203-2209. Future Medicine Ltd.مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Axitinib, medicine.medical_treatment, Antibodies, Monoclonal, Humanized, Nephrectomy, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Secondary Prevention, medicine, Humans, Carcinoma, Renal Cell, Survival rate, Neoadjuvant therapy, Aged, business.industry, Sunitinib, Standard treatment, Antibodies, Monoclonal, General Medicine, Middle Aged, medicine.disease, Neoadjuvant Therapy, 030104 developmental biology, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::369bb6ff466aca46df9eb0681ca38bf3Test
https://doi.org/10.2217/fon-2019-0111Test -
8
المؤلفون: Thomas Eigentler, Cindy Franklin, Anja Gesierich, Claus Garbe, Sebastian Haferkamp, James Larkin, Sophia Kreft, Paul Lorigan, Bastian Schilling, Sara Valpione, Selma Ugurel, Jochen Utikal, Dirk Schadendorf, Christian U. Blank
المصدر: European Journal of Cancer. 116:207-215
مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Medizin, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Targeted therapy, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, medicine, Humans, Molecular Targeted Therapy, Adverse effect, Melanoma, Aged, Retrospective Studies, Aged, 80 and over, Salvage Therapy, business.industry, Immunotherapy, Middle Aged, medicine.disease, Confidence interval, Nivolumab, Treatment Outcome, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0f33bef3ecdaf233f4184cbdb0bbc1eTest
https://doi.org/10.1016/j.ejca.2019.05.015Test -
9
المؤلفون: James Larkin, Ralf Gutzmer, Andrew Haydon, Paul Lorigan, Rutger H. T. Koornstra, Stéphane Dalle, Adnan Khattak, Alexander C.J. van Akkooi, Alfonsus J M van den Eertwegh, Christian U. Blank, Anna Maria Di Giacomo, Rahima Jamal, Clemens Krepler, Robert J. Lupinacci, Alexander M.M. Eggermont, Jean-Jacques Grob, Stefan Suciu, Leonel Hernandez-Aya, Caroline Robert, Matteo S. Carlino, Piotr Rutkowski, Nageatte Ibrahim, Mario Mandalà, Sandrine Marreaud, Georgina V. Long, Dirk Schadendorf, Paolo A. Ascierto, Michal Kicinski, Susana Puig, Victoria Atkinson, Shahneen Sandhu, Mikhail Lichinitser
المساهمون: Medical oncology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology
المصدر: Ann Transl Med
European Journal of Cancer, 116, pp. 148-157
European Journal of Cancer, 116, 148-157. Pergamon
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Lupinacci, R, Krepler, C, Ibrahim, N, Kicinski, M, Marreaud, S, van Akkooi, A C, Suciu, S & Robert, C 2019, ' Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 116, pp. 148-157 . https://doi.org/10.1016/j.ejca.2019.05.020Test
European Journal of Cancer, 116, 148-157مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, medicine.medical_treatment, Medizin, Pembrolizumab, Metastasis, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Antineoplastic Agents, Immunological, Adjuvant therapy, AJCC-7, AJCC-8, EORTC 1325/KN-054, Melanoma, Phase III trial, Predictive factors, Prognostic factors, Adult, Aged, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Treatment Outcome, Monoclonal, Humanized, Hazard ratio, Editorial Commentary, Immunological, 030220 oncology & carcinogenesis, medicine.drug, medicine.medical_specialty, Antineoplastic Agents, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, business.industry, Cancer, medicine.disease, 030104 developmental biology, Lymphadenectomy, business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e8c4fb38d782241aa3a6b2f75643c8Test
https://hdl.handle.net/2066/206244Test -
10
المؤلفون: Paolo A. Ascierto, Serigne Lo, Carlo Tondini, Richard D. Carvajal, Karijn P M Suijkerbuijk, Kerry L. Reynolds, Jessica S.W. Borgers, Jeremy Lupu, Christian U. Blank, Séverine Roy, Christian Posch, Michael Erdmann, Mario Mandalà, Ines Pires da Silva, Matteo S. Carlino, Maria Grazia Vitale, Tim Cooksley, F. Stephen Hodi, Megan H. Trager, Carola Berking, Leyre Zubiri, Laura Pala, Sharon Nahm, Dirk Schadendorf, Paola Queirolo, Alon Vaisman, Neha Papneja, Paul Lorigan, Joanna Mangana, Aljosja Rogiers, Alexander M. Menzies, Thiago Pimentel Muniz, Caroline Robert, Ryan J. Sullivan, John B. A. G. Haanen, Marcus O. Butler, Reinhard Dummer, Peter Bowling, Wilson H. Miller, Osama E. Rahma, Arielle Elkrief, Samuel D. Saibil, Chiara Tentori, Joseph M. Grimes, Michael Manos, Lisa Zimmer, Georgina V. Long, April A.N. Rose, Axel Hauschild
المصدر: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer
Rogiers, A, Da Silva, I P, Tentori, C, Tondini, C A, Grimes, J M, Trager, M H, Nahm, S, Zubiri, L, Manos, M, Bowling, P, Elkrief, A, Papneja, N, Vitale, M G, Rose, A A N, Borgers, J S W, Roy, S, Mangana, J, Pimentel Muniz, T, Cooksley, T, Lupu, J, Vaisman, A, Saibil, S D, Butler, M O, Menzies, A M, Carlino, M S, Erdmann, M, Berking, C, Zimmer, L, Schadendorf, D, Pala, L, Queirolo, P, Posch, C, Hauschild, A, Dummer, R, Haanen, J, Blank, C U, Robert, C, Sullivan, R J, Ascierto, P A, Miller, W H, Stephen Hodi, F, Suijkerbuijk, K P M, Reynolds, K L, Rahma, O E, Lorigan, P C, Carvajal, R D, Lo, S, Mandala, M & Long, G V 2021, ' Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition ', Journal for ImmunoTherapy of Cancer, vol. 9, no. 1, e001931 . https://doi.org/10.1136/jitc-2020-001931Test
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)مصطلحات موضوعية: Male, 0301 basic medicine, Cancer Research, viruses, Medizin, law.invention, Cohort Studies, 0302 clinical medicine, law, Neoplasms, Immunology and Allergy, Immune Checkpoint Inhibitors, RC254-282, Cause of death, Aged, 80 and over, Clinical/Translational Cancer Immunotherapy, education.field_of_study, Manchester Cancer Research Centre, Mortality rate, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, virus diseases, Middle Aged, Intensive care unit, ddc, Oncology, 030220 oncology & carcinogenesis, Molecular Medicine, Female, immunotherapy, Adult, medicine.medical_specialty, Immunology, Population, macromolecular substances, 03 medical and health sciences, Internal medicine, Intensive care, medicine, Humans, ddc:610, Ticilimumab, Risk factor, education, Aged, Retrospective Studies, Pharmacology, SARS-CoV-2, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, COVID-19, Cancer, biochemical phenomena, metabolism, and nutrition, medicine.disease, Coronavirus, 030104 developmental biology, nervous system, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08a1cc9e235765fb1d6543b99dc04cb3Test
http://europepmc.org/articles/PMC7817383Test